COMPANY NEWS

  • Home
  • ▶
  • Company News
June 12, 2025
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
June 10, 2025
Travere Therapeutics Launches “Play It Forward” Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
June 3, 2025
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
May 15, 2025
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
May 12, 2025
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2025
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 1, 2025
Travere Therapeutics Reports First Quarter 2025 Financial Results
April 29, 2025
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 24, 2025
Travere Therapeutics to Report First Quarter 2025 Financial Results
March 17, 2025
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 12, 2025
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)